The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis

Published:2022-06 Issue: Volume:20 Page:101375
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Cao Jinlong^ORCID,Yang Xin,Chen Siyu,Wang Jirong,Fan Xinpeng,Fu Shengjun,Yang Li

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference67 articles.

1. The ever-increasing importance of cancer as a leading cause of premature death worldwide;Bray;Cancer,2021

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

3. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer;Carbone;N. Engl. J. Med.,2017

4. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy;Cristescu;Science,2018

5. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer;Dolladille;JAMA Oncol.,2020

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole-Exome Sequencing of Vulvar Squamous Cell Carcinomas Reveals an Impaired Prognosis in Patients With TP53 Mutations and Concurrent CCND1 Gains;Modern Pathology;2024-10

2. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden;Journal for ImmunoTherapy of Cancer;2024-08

3. Harnessing the capacity of phytochemicals to enhance immune checkpoint inhibitor therapy of cancers: A focus on brain malignancies;Cancer Letters;2024-07

4. Testing for genomic biomarkers in non-small-cell lung cancer;Diagnostic Histopathology;2024-07

5. Immune- and metabolism-related gene signature analysis uncovers the prognostic and immune microenvironments of hepatocellular carcinoma;Journal of Cancer Research and Clinical Oncology;2024-06-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3